Pseudomonas aeruginosa

20,421views

Pseudomonas aeruginosa

MSKS

MSKS

Introduction to the skeletal system
Introduction to the muscular system
Bone histology
Cartilage histology
Skeletal muscle histology
Bone remodeling and repair
Cartilage structure and growth
Fibrous, cartilage, and synovial joints
Radial head subluxation (Nursemaid elbow)
Developmental dysplasia of the hip
Legg-Calve-Perthes disease
Slipped capital femoral epiphysis
Transient synovitis
Osgood-Schlatter disease (traction apophysitis)
Rotator cuff tear
Klumpke paralysis
Spondylolysis
Spondylolisthesis
Degenerative disc disease
Spinal disc herniation
Sciatica
Compartment syndrome
Rhabdomyolysis
Craniosynostosis
Osteogenesis imperfecta
Cleidocranial dysplasia
Achondroplasia
Osteomyelitis
Bone tumors
Osteochondroma
Chondrosarcoma
Osteoporosis
Osteomalacia and rickets
Paget disease of bone
Osteopetrosis
Osteoarthritis
Spondylosis
Spinal stenosis
Rheumatoid arthritis
Juvenile idiopathic arthritis
Gout
Calcium pyrophosphate deposition disease (pseudogout)
Psoriatic arthritis
Ankylosing spondylitis
Reactive arthritis
Spondylitis
Septic arthritis
Bursitis
Baker cyst
Polymyositis
Dermatomyositis
Inclusion body myopathy
Polymyalgia rheumatica
Fibromyalgia
Rhabdomyosarcoma
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Citric acid cycle
Slow twitch and fast twitch muscle fibers
Electron transport chain and oxidative phosphorylation
Glycolysis
Selective permeability of the cell membrane
Resting membrane potential
Neuron action potential
Fatty acid oxidation
Amino acid metabolism
Ketone body metabolism
Skeletal system anatomy and physiology
Muscular system anatomy and physiology
Brachial plexus
Neuromuscular junction and motor unit
Sliding filament model of muscle contraction
Muscle contraction
Muscle spindles and golgi tendon organs
Neuromuscular blockers
Neuromuscular junction disorders: Pathology review
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Glycogen storage disease type II (NORD)
Glycogen storage disease type I
Glycogen storage disease type V
Glycogen storage disease type IV
Glycogen storage disease type III
Muscular dystrophies and mitochondrial myopathies: Pathology review
Myalgias and myositis: Pathology review
Shock
Escherichia coli
Staphylococcus aureus
Clostridium tetani (Tetanus)
Clostridium botulinum (Botulism)
Abdominal trauma: Clinical
Neck trauma: Clinical
Chest trauma: Clinical
Traumatic brain injury: Clinical
Complement system
Clostridium perfringens
Streptococcus pyogenes (Group A Strep)
Neisseria gonorrhoeae
Non-steroidal anti-inflammatory drugs
Acetaminophen (Paracetamol)
Rheumatoid arthritis and osteoarthritis: Pathology review
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Gout and pseudogout: Pathology review
Pseudomonas aeruginosa
Salmonella (non-typhoidal)
Pediatric bone and joint infections: Clinical
Back pain: Pathology review
Lower back pain: Clinical
Skin and soft tissue infections: Clinical
Bone tumors: Pathology review
Pediatric orthopedic conditions: Clinical
Uterine fibroid
Erb-Duchenne palsy
Seronegative and septic arthritis: Pathology review
Vaccinations: Clinical
Vaccinations
Cardiac muscle histology
Cardiac excitation-contraction coupling
Positive inotropic medications
cGMP mediated smooth muscle vasodilators
Calcium channel blockers
Adrenergic antagonists: Beta blockers
Marfan syndrome
Ehlers-Danlos syndrome

Flashcards

Pseudomonas aeruginosa

0 of 37 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 7 complete

Start
A 23-year-old man was admitted five days ago to the burn ward after suffering severe lower extremity burns at work. On admission, the patient was started on prophylactic antibiotics. Currently, temperature is 39 ºC (102.2 ºF), pulse is 120/minute, blood pressure is 98/55, and respirations are 20/minute. Examination of the burn wounds shows blue-green purulent discharge. Microscopic and laboratory examination of the discharge show Gram-negative catalase-positive bacteria. Which of the following organisms is the most likely cause of this patient’s condition?  

Transcript

Watch video only

Content Reviewers

Pseudomonas aeruginosa, or P. aeruginosa, is a gram-negative bacterium that is abundant in the environment.

It tends to opportunistically infect high-risk individuals, and is well known for its multi-drug resistance, making it hard to treat.

P. aeruginosa is an encapsulated, gram-negative, rod bacterium, that’s an obligate aerobe, so it uses oxygen for metabolism through cellular respiration.

It does not ferment lactose and does not make spores; but it’s catalase, citrate, and oxidase positive.

It has a flagellum, kind of like a tail, at one end for motility; and has multiple hair-like appendages, called pili, all over that help with adhesion to other cells.

It also has a number of multidrug efflux pumps that efficiently pump medications out of the bacteria making it resistant to a variety of antibiotics.

In addition it’s able to make beta-lactamases that degrade beta-lactam antibiotics as well as aminoglycoside-modifying enzymes that alter aminoglycoside antibiotics - rendering them ineffective. In short, it’s defenses are strong.

P. aeruginosa is everywhere in the environment - in soil; in the home, and in hospitals - where it’s found on improperly cleaned medical equipment and devices, various surfaces, and on the hands of health care workers.

It can survive for months on dry surfaces and inanimate objects – but particularly loves humid or wet conditions; like hot tubs, contact lens cases, catheters, and medical ventilators.

Transmission can occur when broken skin or mucous membranes come in contact with contaminated surfaces; or when aerosols containing P. aeruginosa are inhaled after an infected person coughs or sneezes.

Now, a P. aeruginosa infection is actually not too common in the general population.

It’s an opportunistic bacterium, meaning that it frequently causes infections in high-risk individuals like those with cystic fibrosis, chronic granulomatous disease, and type 2 diabetes mellitus.

It’s also common among individuals with an immunodeficiency; IV drug abusers, or those with severe burns or deep wounds.

P. aeruginosa produces several virulence factors to help it invade epithelial cells and survive an attack from the immune system.

First, there’s endotoxin, a molecule that’s made up of a lipid and polysaccharide.

The endotoxin sits on the outer membrane of the bacteria, and it’s recognized by the immune system as being foreign and causes a really strong immune reaction that can cause extensive damage to the host cells.

Certain strains of P. aeruginosa also produce a mucoid exopolysaccharide capsule, and this contributes to the formation of a biofilm - a slimy, sticky, gummy material – that surrounds colonies of P. aeruginosa and acts like a shield to protect the bacteria from immune cells as well as antibiotics.

P. aeruginosa can also produce toxins that can be injected directly into the host epithelial cells through a type III secretion system.

It’s kind of like a fine needle that pierces the host cell and forms a tunnel between the P. aeruginosa and the host epithelial cell, allowing toxins to pass through.

P. aeruginosa also releases toxins into the extracellular environment.

For example, it releases phospholipase C which is an enzyme that degrades the host cell membrane causing the cell to lyse.

Other secreted toxins have to move within the cell to act.

For example, exotoxin A is released by P. aeruginosa into the extracellular environment and then taken up by nearby host cells where it targets ADP-ribosylation of elongation factor 2, which is a ribosomal protein.

Key Takeaways

Pseudomonas aeruginosa is an aerobic, gram-negative, rod-shaped bacterium commonly found in the environment, such as in soil, in the home, and in hospitals. It is known to opportunistically infect immunocompromised people, and for its multi-drug resistance that is hard to treat.

It is also known to form biofilms that provide it with extra protection against antibiotics on top of its preexisting multi-drug resistance. P. aeruginosa can cause a variety of infections, including urinary tract infections, wound infections, sepsis, and lung infections in people with cystic fibrosis. Treatment for P. aeruginosa infections is with antibiotics, such as aminoglycosides, carbapenems, and cephalosporins.